Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341

Robert Buzzeo, Steven Enkemann, Rama Nimmanapalli, Melissa Alsina, Mathias G Lichtenheld, William S. Dalton, Darrin M. Beaupre

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The farnesyl transferase inhibitor R115777 has been found to have clinical activity in diverse hematopoietic tumors. Clinical efficacy, however, does not correlate with Ras mutation status or inhibition of farnesyl transferase. To further elucidate the mechanisms by which R115777 induces apoptosis and to investigate drug resistance, we have identified and characterized a R115777-resistant human myeloma cell line. 8226/R5 cells were found to be at least 50 times more resistant to R115777 compared with the parent cell line 8226/S. K-Ras remained prenylated in both resistant and sensitive cells after R115777 treatment; however, HDJ-2 farnesylation was inhibited in both lines, implying that farnesyl transferase (the drug target) has not been mutated. Whereas many 8226 lines that acquire drug resistance have elevated expression of P-glycoprotein, we found that P-glycoprotein expression is not increased in the 8226/R5 line and intracellular accumulation of R115777 was not reduced. In fact, 8226/R5 cells were insensitive to a diverse group of antitumor agents including PS-341, and multidrug resistance did not correlate with the expression of heat shock proteins. Comparison of gene expression profiles between resistant and sensitive cells revealed expression changes in several genes involved in myeloma survival and drug resistance. Future experiments will attempt to identify genes that are directly linked to the resistant phenotype. Identification of molecules associated with R115777 and PS-341 resistance is clinically relevant because both compounds are being tested in solid tumors and hematopoietic malignancies.

Original languageEnglish
Pages (from-to)6057-6064
Number of pages8
JournalClinical Cancer Research
Volume11
Issue number16
DOIs
StatePublished - Aug 15 2005

Fingerprint

tipifarnib
Multiple Myeloma
Cell Line
Transferases
Drug Resistance
P-Glycoprotein
Prenylation
Multiple Drug Resistance
Hematologic Neoplasms
Heat-Shock Proteins
Bortezomib
Transcriptome
Antineoplastic Agents
Genes
Neoplasms
Apoptosis
Phenotype

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. / Buzzeo, Robert; Enkemann, Steven; Nimmanapalli, Rama; Alsina, Melissa; Lichtenheld, Mathias G; Dalton, William S.; Beaupre, Darrin M.

In: Clinical Cancer Research, Vol. 11, No. 16, 15.08.2005, p. 6057-6064.

Research output: Contribution to journalArticle

Buzzeo, Robert ; Enkemann, Steven ; Nimmanapalli, Rama ; Alsina, Melissa ; Lichtenheld, Mathias G ; Dalton, William S. ; Beaupre, Darrin M. / Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 16. pp. 6057-6064.
@article{83fb60133d654b408a5b0d8c0021475a,
title = "Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341",
abstract = "The farnesyl transferase inhibitor R115777 has been found to have clinical activity in diverse hematopoietic tumors. Clinical efficacy, however, does not correlate with Ras mutation status or inhibition of farnesyl transferase. To further elucidate the mechanisms by which R115777 induces apoptosis and to investigate drug resistance, we have identified and characterized a R115777-resistant human myeloma cell line. 8226/R5 cells were found to be at least 50 times more resistant to R115777 compared with the parent cell line 8226/S. K-Ras remained prenylated in both resistant and sensitive cells after R115777 treatment; however, HDJ-2 farnesylation was inhibited in both lines, implying that farnesyl transferase (the drug target) has not been mutated. Whereas many 8226 lines that acquire drug resistance have elevated expression of P-glycoprotein, we found that P-glycoprotein expression is not increased in the 8226/R5 line and intracellular accumulation of R115777 was not reduced. In fact, 8226/R5 cells were insensitive to a diverse group of antitumor agents including PS-341, and multidrug resistance did not correlate with the expression of heat shock proteins. Comparison of gene expression profiles between resistant and sensitive cells revealed expression changes in several genes involved in myeloma survival and drug resistance. Future experiments will attempt to identify genes that are directly linked to the resistant phenotype. Identification of molecules associated with R115777 and PS-341 resistance is clinically relevant because both compounds are being tested in solid tumors and hematopoietic malignancies.",
author = "Robert Buzzeo and Steven Enkemann and Rama Nimmanapalli and Melissa Alsina and Lichtenheld, {Mathias G} and Dalton, {William S.} and Beaupre, {Darrin M.}",
year = "2005",
month = "8",
day = "15",
doi = "10.1158/1078-0432.CCR-04-2685",
language = "English",
volume = "11",
pages = "6057--6064",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341

AU - Buzzeo, Robert

AU - Enkemann, Steven

AU - Nimmanapalli, Rama

AU - Alsina, Melissa

AU - Lichtenheld, Mathias G

AU - Dalton, William S.

AU - Beaupre, Darrin M.

PY - 2005/8/15

Y1 - 2005/8/15

N2 - The farnesyl transferase inhibitor R115777 has been found to have clinical activity in diverse hematopoietic tumors. Clinical efficacy, however, does not correlate with Ras mutation status or inhibition of farnesyl transferase. To further elucidate the mechanisms by which R115777 induces apoptosis and to investigate drug resistance, we have identified and characterized a R115777-resistant human myeloma cell line. 8226/R5 cells were found to be at least 50 times more resistant to R115777 compared with the parent cell line 8226/S. K-Ras remained prenylated in both resistant and sensitive cells after R115777 treatment; however, HDJ-2 farnesylation was inhibited in both lines, implying that farnesyl transferase (the drug target) has not been mutated. Whereas many 8226 lines that acquire drug resistance have elevated expression of P-glycoprotein, we found that P-glycoprotein expression is not increased in the 8226/R5 line and intracellular accumulation of R115777 was not reduced. In fact, 8226/R5 cells were insensitive to a diverse group of antitumor agents including PS-341, and multidrug resistance did not correlate with the expression of heat shock proteins. Comparison of gene expression profiles between resistant and sensitive cells revealed expression changes in several genes involved in myeloma survival and drug resistance. Future experiments will attempt to identify genes that are directly linked to the resistant phenotype. Identification of molecules associated with R115777 and PS-341 resistance is clinically relevant because both compounds are being tested in solid tumors and hematopoietic malignancies.

AB - The farnesyl transferase inhibitor R115777 has been found to have clinical activity in diverse hematopoietic tumors. Clinical efficacy, however, does not correlate with Ras mutation status or inhibition of farnesyl transferase. To further elucidate the mechanisms by which R115777 induces apoptosis and to investigate drug resistance, we have identified and characterized a R115777-resistant human myeloma cell line. 8226/R5 cells were found to be at least 50 times more resistant to R115777 compared with the parent cell line 8226/S. K-Ras remained prenylated in both resistant and sensitive cells after R115777 treatment; however, HDJ-2 farnesylation was inhibited in both lines, implying that farnesyl transferase (the drug target) has not been mutated. Whereas many 8226 lines that acquire drug resistance have elevated expression of P-glycoprotein, we found that P-glycoprotein expression is not increased in the 8226/R5 line and intracellular accumulation of R115777 was not reduced. In fact, 8226/R5 cells were insensitive to a diverse group of antitumor agents including PS-341, and multidrug resistance did not correlate with the expression of heat shock proteins. Comparison of gene expression profiles between resistant and sensitive cells revealed expression changes in several genes involved in myeloma survival and drug resistance. Future experiments will attempt to identify genes that are directly linked to the resistant phenotype. Identification of molecules associated with R115777 and PS-341 resistance is clinically relevant because both compounds are being tested in solid tumors and hematopoietic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=23844540638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844540638&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-2685

DO - 10.1158/1078-0432.CCR-04-2685

M3 - Article

VL - 11

SP - 6057

EP - 6064

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 16

ER -